Exagen Analyst Ratings
Exagen's Strong Q1 Earnings and Growth Potential Justify Buy Rating
Buy Rating Affirmed for Exagen Amid Strong Sales Growth and Promising Outlook
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives
Exagen's Strong Q4 Performance and Positive Outlook Justify Buy Rating
Exagen (XGN) Receives a Buy From BTIG
Exagen (XGN) Gets a Buy From BTIG
Exagen (XGN) Gets a Buy From Cantor Fitzgerald
Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)
Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target
Exagen Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target
Exagen Analyst Ratings
Cantor Fitzgerald Reaffirms Their Buy Rating on Exagen (XGN)
Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Exagen (XGN)
BTIG Adjusts Price Target on Exagen to $5 From $6, Maintains Buy Rating
BTIG Maintains Buy on Exagen, Lowers Price Target to $5
BTIG Keeps Their Buy Rating on Exagen (XGN)
BTIG Adjusts Exagen's Price Target to $7 From $10, Keeps Buy Rating